What question did this study set out to answer?

To evaluate the prevalence of druggable genetic aberrations and the clinical utility of comprehensive genomic profiling in advanced NSCLC.

June 4, 2026Thoracic CancerOpen Access

Clinical Utility of Comprehensive Genomic Profiling for Advanced Non‐Small Cell Lung Cancer: A Single‐Center Retrospective Study

View Full Paper

Ask AI

Bookmark

Authors

Retrospective study evaluates genomic profiling's impact on treatment in advanced NSCLC, suggesting new therapeutic strategies.

To evaluate the prevalence of druggable genetic aberrations and the clinical utility of comprehensive genomic profiling in advanced NSCLC.
Retrospective analysis of 108 patients with advanced NSCLC treated at Kanagawa Cancer Center Hospital
Comprehensive genomic profiling performed using OncoGuide NCC Oncopanel System, FoundationOne, and FoundationOne Liquid
Assessment of druggable mutations and resistance mechanisms post-standard treatment
Druggable genetic aberrations detected in 37% of patients; EGFR mutations were most common.
Non-smokers had a higher rate of druggable mutations (55.6%) compared to smokers (27.8%).
Patients receiving genomically matched therapy showed a trend toward prolonged overall survival (log-rank p = 0.054).

Murakami et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark